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Protein bindingPericardial tuberculosis (TB) is associated with high therapy failure and high mortality rates. Antibiotics have to
penetrate to site of infection at sufﬁcient non-protein bound concentrations, and then enter bacteria to inhibit in-
tracellular biochemical processes. The antibiotic concentrations achieved in pericardial ﬂuid in TB pericarditis
have never been measured before. We recruited two cohorts of patients with TB pericarditis, and left a pigtail
catheter in-situ for serial drug concentration measurements over 24 h. Altogether, 704 drug concentrations
were comodeled for pharmacokinetic analyses. The drug concentrations achieved in pericardial ﬂuid were com-
pared to the minimum inhibitory concentrations (MICs) of clinicalMycobacterium tuberculosis isolates. The total
rifampicin concentration pericardial-to-serum ratios in 16 paired sampleswere 0.19± 0.33. The protein concen-
trations of the pericardialﬂuid in TBpericarditiswere observed to be as high as in plasma. The non-protein bound
rifampicin concentrations in pericardial ﬂuid were 4-fold lower than rifampicin MICs in the pilot study, and the
peak concentration was 0.125 versus 0.208 mg/L in the second (p= 0.001). The rifampicin clearance from peri-
cardial ﬂuid was 9.45 L/h versus 7.82 L/h in plasma (p = 0.002). Ethambutol peak concentrations had a
pericardial-to-plasma ratio of 0.55 ± 0.22; free ethambutol peak concentrations were 2.30-lower than MICs
(p b 0·001). The pericardial ﬂuid pH was 7.34. The median pyrazinamide peak concentrations were
42.93mg/L versus amedianMIC of 800mg/L at pH7.34 (pb 0.0001). Therewasno signiﬁcant difference between
isoniazid pericardial ﬂuid and plasma concentrations, and isoniazid peak concentrations were above MIC. This is
the ﬁrst study tomeasure anti-TB drug concentrations, pH and protein in the pericardial TB ﬂuid. Pericardial con-
centrations of the key sterilizing drugs for TB were belowMIC, which could contribute to poor outcomes. A new
regimen that overcomes these limitations might need to be crafted.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculous pericarditis is a common medical condition in many
countries in Africa and Asia (Mayosi et al., 2005; Mayosi et al., 2006;
Cherian, 2004). Despite treatment, one in every four patients is dead
within six months, and close to one in two patients with human immu-
nodeﬁciency virus (HIV) co-infection are dead within six months
(Mayosi et al., 2005). We have recently completed the Investigation of
the Management of Pericarditis (IMPI) study, a randomized controlled
trial examining the effects of either prednisolone or Mycobacterium
indicus pranii or both and the standard regimen (isoniazid, rifampin,
ethambutol and pyrazinamide) in 1400 patients (Mayosi et al., 2014).
The primary composite outcome (death, cardiac tamponade requiringses Research and Experimental
eet, Dallas, TX 75204, USA.
. Gumbo).
. This is an open access article underpericardiocentesis, or constrictive pericarditis) rate was approximately
15 events per 100 patient-years of follow-up; the main causes of
death were either the pericarditis or disseminated tuberculosis (TB) in
greater than 42% of deaths. These outcomes were encountered despite
adherence to treatment in about 90% of patients, and are thus attribut-
able to primary failure of standard therapy. The reasons for therapy fail-
ure are unclear, but could include high bacterial burden, concurrent
immunodeﬁciency, or treatment factors that could be summarized as
antimicrobial pharmacokinetics/pharmacodynamics (PK/PD) (Gumbo
et al., 2015a; Craig, 1998). PK/PD science relates drug concentration of
antibiotics at site of infection tomicrobial kill and resistance emergence;
non-protein bound concentrations are central to pharmacodynamics ef-
fects (Gumbo et al., 2015a; Craig, 1998; Gumbo, 2011; Ambrose et al.,
2007; Pasipanodya and Gumbo, 2011; Zeitlinger et al., 2011).
First-line anti-TB drugs exert their effect by binding directly to the
bacterial targets inside the Mycobacterium tuberculosis (Mtb) cells.
Only non-protein bound drug concentrations enter bacteria. Therefore,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to achieve adequate free-drug concentrations in the pericardial space.
The antibacterial effect of rifampicin, isoniazid, ethambutol and
pyrazinamide is closely linked to speciﬁc peak concentration, 0–24 h
area under the concentration–time curve (AUC0–24), and minimum in-
hibitory concentration (MIC) (Gumbo et al., 2007a; Gumbo et al.,
2007b; Gumbo et al., 2009; Pasipanodya et al., 2013; Srivastava et al.,
2010; Chigutsa et al., 2015). Utilizing standard treatment of pulmonary
TB, recommended doses barely achieve these target concentrations
(Gumbo et al., 2007a; Gumbo et al., 2007b; Gumbo et al., 2009;
Pasipanodya et al., 2013; Srivastava et al., 2010; Chigutsa et al., 2015).
Moreover, despite administration of recommended doses, between-
patient pharmacokinetic variability leads substantial proportions of pa-
tients to metabolize some of the drugs more extensively than others,
who may end up on effective monotherapy, therapy failure, and ac-
quired drug resistance (Pasipanodya et al., 2013; Srivastava et al.,
2011a; Pasipanodya et al., 2012). It is unknown to what extent these
drugs penetrate into pericardial space, or the variability thereof. We
performed two sets of sub-studies during the ongoing IMPI registry
(Mayosi et al., 2006; Mayosi et al., 2008), a pilot study to identify the ri-
fampicin concentrations in paired plasma and pericardial ﬂuid samples,
followed by a second more intensive pericardial ﬂuid pharmacokinetic
sampling study for all four anti-TB drugs. The ﬁndings of these studies
are reported herein.2. Methods
2.1. Ethics
Institutional review board and ethical considerations were pub-
lished before in publications on the baseline characteristics and out-
comes of patients enrolled in the IMPI registry. (Mayosi et al., 2006;
Mayosi et al., 2008) For each study, either the registry or clinical trial,
approval was received from the appropriate South African regulatory
authority and by the University of Cape Town Ethics Committee. In-
formed consent formswere available in isiXhosa, Afrikaans, and English.
The IMPI trial was registered at clinicaltrials.gov (NCT00810849).2.2. Setting
Both the pilot and intensive sampling pharmacokinetic sub-studies
were performed at Groote Schuur Hospital in Observatory, Cape Town,
South Africa. The pilot study was performed between June and
December 2011. The intensive pharmacokinetic sampling study was
performed between October 2012 and June 2014.2.3. Case Deﬁnition
Patients 18 years or older, were enrolled if they had deﬁnite or
probable pericardial TB, based on a TB pericarditis case deﬁnition
(Mayosi et al., 2005; Mayosi et al., 2014; Reuter and Burgess, 2006;
Pandie et al., 2014). Deﬁnite TB pericarditis patients were those
with conﬁrmed pericardial TB, based on either the presence of acid
and alcohol fast bacilli on microscopy of pericardial ﬂuid, presence
of Mtb by culture or by nucleic acid test in pericardial ﬂuid or tissue,
or histologic evidence of caseating granulomata. Probable TB peri-
carditis patients did not have evidence of these microbial, nucleic
acid, or histological features, in pericardial ﬂuid or tissue, but had
evidence of TB at another anatomical location and/or presence of a
lymphocytic pericardial exudate with elevated adenine deaminase
or a Tygerberg TB Pericarditis Diagnostic Index Score ≥6 (Mayosi
et al., 2005; Mayosi et al., 2014; Reuter and Burgess, 2006; Pandie
et al., 2014).2.4. Pilot Study
The pilot study sample size was set based on precedence of some of
our prior pharmacokinetic studies of anti-TB agents (Hall et al., 2012).
Consecutive patients scheduled to undergo pericardiocentesis as part
of their routine care provided informed written consent. Patients had
the four-drug standard therapy regimen administered under supervi-
sion of a study nurse, after which they underwent pericardiocentesis.
At the time of study, most patients were treated with Rifafour®, each
containing rifampin 150 mg, isoniazid 75 mg, pyrazinamide 400 mg,
and ethambutol 275 mg (ﬁxed dose combination or FDC). Without in-
terfering with patients' scheduled time for pericardiocentesis, the
timing of drug therapy was set to allow for sampling time points
scattered through the 24 h dosing interval. At each of several time
points, simultaneous blood and pericardial ﬂuid samples were drawn,
placed on ice, processed, and stored at−80 °C.
2.5. Intensive Sampling Study
Demographic data, clinical information and laboratory data were
collected, including age, sex, weight, HIV status, and concomitant med-
ication. Serum total protein and globulin were taken at the time of
enrolment. Echocardiography, followed by ﬂuoroscopy guided
pericardiocentesis using the Seldinger technique was performed. The
pericardial effusionwas drained to “dryness” (to the point of no residual
drainage) and a pigtail catheter was left in-situ. Antibiotic therapy was
administered under direct supervision, after which simultaneous
blood and pericardial ﬂuid samples were collected at 0 (before drug ad-
ministration), 30 min, 1, 2, 3, 5, 8 and 24 h post-dose in heparinized
tubes. The samples were also collected in ethylenediaminetetraacetic
acid (EDTA), centrifuged at 2000 relative centrifugal force for 10 min,
after which supernatant was collected and stored at−80 °C.
2.6. Drug Assays
The determination of concentrations in plasma and pericardial ﬂuid
was accomplished using validated tandem mass spectrometry high-
performance liquid chromatography-tandem mass spectrometry (LC-
MS/MS). The methods were validated in plasma and cross validated in
pericardial ﬂuid.
For quantiﬁcation of isoniazid in 20 μL of K3EDTA human plasma,
protein precipitation with 0.1% acetic acid in acetonitrile was followed
by chromatographic separation on a Kinetex Hilic C18, 2.6 μm column.
For quantiﬁcation of pyrazinamide from 20 μL human plasma, protein
precipitation was achieved using a mixture of methanol and acetoni-
trile, and chromatographic separation on an Atlantis T3 C18, 3 μm col-
umn under isocratic conditions. For rifampicin and ethambutol
quantiﬁcation from 20 μL plasma, protein precipitation was achieved
with acetonitrile, followed by separation on a Discovery C18, 5 μ, col-
umn for rifampicin, and a Phenomenex Onyx Monolith C18
(100 × 3.0 mm) column for ethambutol. An AB Sciex API 3000 mass
spectrometer was operated in the multiple reactions monitoring
(MRM) mode, monitoring the transitions 138.1 to 79.1 for isoniazid,
124.0 to 81.4 for pyrazinamide, 823.4 to 791.4 for rifampicin, and
205.2 to 116.2 for ethambutol.
The assays were validated over the concentration range of
0.102 μg/mL to 26.0 μg/mL for isoniazid, 0.203 μg/mL to 81.1 μg/mL
for pyrazinamide, 0.117 μg/mL to 30 μg/mL for rifampicin, and
0.0844 μg/mL to 5.40 μg/mL for ethambutol. The between-day
mean percentage accuracies for isoniazid were 101.0%, 103.2%, and
96.0%, those for pyrazinamidewere 96.5%, 95.5% and 98.2%, for rifampi-
cin 102.2%, 99.6% and 101.7%, and those for ethambutol were 98.5%,
101.3% and 99.0% at the high, medium, and low quality control (QC)
levels, respectively. The level of precision had a coefﬁcient of variation
(% CV) of less than 13% at low, medium, and high QC levels for all
analytes.
Table 1
Clinical and demographic characteristics in pilot study patients.
Variable Mean Range
Age in years 35.2 19.2–48.9
Time from dose to sample collection (hr) 4.82 1–24
Diastolic blood pressure (mmHg) 69.6 60–90
Hemoglobin (g/L) 9.7 5.9–14.3
White cell count × 103 cells/μL 5.73 3.6–9.8
CD4+ cells/mL 307 263a
Adenosine deaminase (U/L) 56.9 70–133.2
Pericardial ﬂuid total protein (g/L) 56.9 38–75
a Standard deviation.
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Our pharmacokinetic studies of several hundred patients in the
same Cape Town population as well as from elsewhere in the past
have identiﬁed rifampicin, isoniazid, and pyrazinamide as one-
compartment model drugs, and ethambutol and isoniazid as two com-
partment drugs (Pasipanodya et al., 2013; Hall et al., 2012). The phar-
macokinetics of each of these drugs was modeled and individual drug
exposures were estimated in ADAPT software (Biomedical Simulations
Resource, University of Southern California) assuming the same number
of compartments identiﬁed in past studies. To identify clearance and
volume of distribution in the pericardial space, the pericardial drug con-
centrations were modeled separately in ADAPT and the full 24 h con-
centration–time curve identiﬁed from the pharmacokinetic model.
These were then used to calculate the full AUC0–24 in the pericardium.
2.8. Comparison of Concentrations Achieved to MICs
We compared drug concentrations achieved in pericardium to their
MICs encountered in drug susceptibleMtb isolates in Cape Town, based
on our prior publications (Chigutsa et al., 2015; Gumbo et al., 2014a;
Gumbo et al., 2014b). Isolates from prior studies were used because a
large number is needed in order to accurately identify the correct MIC
distribution. Because the non-protein bound peak-to-MIC and AUC-to-
MIC ratios of the four ﬁrst-line drugs determine microbiological and
clinical outcomes, and because it is a central tenant of PK/PD science
to adjust or calculate the non-protein bound concentrations at site of in-
fection, we calculated the non-bound drug concentrations in pericardial
ﬂuid assuming 90% of rifampicin and 30% of ethambutol are protein
bound (Gumbo et al., 2015a; Craig, 1998; Gumbo, 2011; Ambrose
et al., 2007; Pasipanodya and Gumbo, 2011; Zeitlinger et al., 2011;
Gumbo et al., 2007a; Gumbo et al., 2007b; Gumbo et al., 2009;
Pasipanodya et al., 2013; Srivastava et al., 2010; Chigutsa et al., 2015;
Te Brake et al., 2015; Woo et al., 1996). These drugs are bound to albu-
min (Woo et al., 1996). In normal pericardial ﬂuid, albumin/total pro-
tein ratios are similar to plasma; the albumin ratio is higher in the
pericardial ﬂuid exudate during infection (Ben-Horin et al., 2005;
Kopcinovic and Culej, 2014). Since isoniazid and pyrazinamide are
only 10% protein bound, we used the total concentrations for these
drugs (Gumbo, 2011; Woo et al., 1996).
2.9. Statistical Tests
A non-parametric Mann–Whitney test was used to compare peak,
AUC and clearances in pericardial ﬂuid and in plasma. Similarly, a
non-parametric Mann–Whitney test was used to compare the medians
of non-protein bound concentrations and MICs.
2.10. Role of Funding Source
The South African Medical Research Council (MRC), the Lily and
Ernst Hausmann Research Trust, and the National Institutes of Health
funded the study. These funding agencies were not involved in the de-
sign and conduct of the study; collection,management, analysis, and in-
terpretation of data; and preparation, review, or approval of the
manuscript.
3. Results
Sixteen patients were enrolled in the pilot study. The clinical and de-
mographic features of these patients are shown in Table 1. Ten (63%)
patients were male. Of the 16 patients, 10 were HIV-infected, with the
mean CD4+ count shown in Table 1. All patients, apart from one, re-
ceived four FDC anti-TB tablets (one patient received loose individual
tablets), amounting to rifampicin 600 mg a day, isoniazid 300 mg a
day, pyrazinamide 1600 mg a day, and ethambutol 1100 mg a day.Blood and pericardial ﬂuid were collected commencing 1 h to 24 h
after the dose, as summarized in Table 1. The paired plasma and pericar-
dial rifampicin concentrations are shown in Fig. 1A. The dramatic differ-
ence illustrated in the ﬁgure, is summarized by ratio of rifampicin
pericardial ﬂuid concentration to plasma concentration of 0.19 ± 0.33
for paired samples. Fig. 1B compares the distribution of all the non-
protein bound rifampicin concentrations to rifampicin MICs inWestern
Cape clinical isolates, and shows that none of the pericardial concentra-
tions, at any sampling time-point, was above theMICs. Themedian con-
centration was 0.125 mg/L and was lower than the median MIC
0.208 mg/L (p= 0.001). However, in the pilot study the timing of sam-
plingwith respect to the antibiotic dosewas varied,which could explain
some of the inter-individual variability of the results, and thus a
more intensive sampling procedure was planned for prior to dose
recommendations.
The pilot study results were used to identify the best sampling times
to assess rifampicin and companion drugs concentrations over a 24-h
period. Eleven patients were enrolled in this more intensive pharmaco-
kinetic sampling study during the IMPI trial. Their clinical and demo-
graphic characteristics are shown in Table 2. Five patients were
allocated to prednisolone, so that patients were split in the middle be-
tween those receiving placebo or immunotherapy, similar to the larger
IMPI trial. All eleven patients received four FDC tablets, amounting to
rifampin 600 mg, isoniazid 300 mg, ethambutol 1100 mg and
pyrazinamide 1600mg each day. One patient was also on antiretroviral
therapy.
The rifampicin concentrations achieved in patients in both the plas-
ma and pericardium are shown in Fig. 2A. The time to peak concentra-
tion in pericardial ﬂuid was a median (range) of 8.18 (6.85–15.40)
hours compared to 3.44 (2.76–3.77) hours in blood (p b 0.0001). The
shape of the concentration time curves in Fig. 2A is characterized by
high plasma peak concentrations and very low and ﬂattened peak con-
centrations in the pericardium. The shape is due to both delay and de-
crease in penetration from the blood into pericardial ﬂuid, as well as
higher rifampicin clearance from pericardial ﬂuid compared to the
blood (Fig. 2A–B). As regards to clearance (Fig. 2B), all patients except
one had higher clearances in pericardium than in blood, and themedian
clearances differed signiﬁcantly (p= 0.002). The non-protein bound ri-
fampicin concentrations in pericardial ﬂuid are also shown in Fig. 2A–D,
which demonstrates very low effective rifampicin concentrations in
pericardial ﬂuid. A comparison of free rifampicin peak concentrations
to MICs encountered in isolates is shown in Fig. 2E, which shows
that the median rifampicin peak concentrations in pericardial ﬂuid,
were lower than the median MIC (p = 0.001).
The ethambutol concentrations achieved in pericardial ﬂuid are
shown in Fig. 3A. The ﬁgure shows that signiﬁcantly lower ethambutol
concentrations were achieved in pericardium compared to plasma
(p b 0.001). Fig. 3A shows similar shapes and time tomaximum concen-
tration between plasma and pericardial ﬂuid. Despite the lower clear-
ance rates in pericardium (Fig. 3B), the ethambutol AUC0–24 in the
pericardiumwas lower than plasma (Fig. 3C). In addition, peak concen-
trations were also lower in pericardium (Fig. 3D). The lower peak and
AUC0–24 in pericardial ﬂuid compared to plasma, despite the lower
Fig. 1. Rifampin concentrations in plasma and pericardium in pilot study. A. The ﬁgure
shows that at all time points the total rifampicin pericardial concentrations were dramat-
ically lower than in the paired plasma. Derived free drug concentrationswere even lower.
B. When all the concentrations at any time point were compared to the MICs, virtually all
were below the MICs. Thus, no non-protein bound concentration was higher than MIC in
pericardial space.
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primarily due to poor penetration. As a result, as shown in Fig. 3E, the
non-protein bound ethambutol concentrations fell below the MICs en-
countered in Western Cape isolates. Indeed, even the total ethambutol
peak concentrationswere below theMICs,without adjusting for protein
binding.Table 2
Clinical and demographic characteristics in patients who underwent intensive pharmaco-
kinetic sampling.
Parameter Mean or proportion Range or %
Sex: male 5 45%
Age in years 37.02 23.98–58.76
Weight in kg 58.36 40–82
Acid-fast bacilli on microscopy 9 82%
HIV-infected 8 73%
Duration of symptoms in weeks 26.77 3–60
Blood counts and concentrations
CD4+ count cells/mL 251 42–874
CD4+ ≤200 cells/mL 7 64%
Creatinine μmol/L 87.00 20–257
Globulin in g/L 47.55 30–56
Pericardial ﬂuid concentrations
Total protein (g/L) 61.18 50–70
Adenosine deaminase (U/L) 77.70 25.90–133.00On the other hand, isoniazid concentrations in the pericardial ﬂuid
approximated those in the plasma in shape, including time tomaximum
concentration (Fig. 4A). Indeed, neither the concentration–time curves,
nor the peak concentrations, nor the clearances, nor the AUCs differed
between pericardial space and plasma (Fig. 4A–D). Since isoniazid is
only 10% protein bound, these total concentrations approximate free
drug concentrations. A comparison between isoniazid peak concentra-
tions and the MICs encountered in Cape Town, which is shown in
Fig. 4E, demonstrates that the isoniazid peak concentrations in pericar-
dial ﬂuid were above MIC. The median peak concentrations were 64-
fold higher than the median MIC (p b 0.001).
Pyrazinamide concentrations in pericardial ﬂuid also closely mir-
rored those in plasma. However, Fig. 5A shows that there was a delay
to peak concentration in pericardial ﬂuid, compared to plasma. Never-
theless, similar peak concentrations were eventually achieved (even
though delayed); the AUCs were similar (Fig. 5B–D). Pyrazinamide re-
quires acidic conditions for activation to killMtb and has zero microbial
kill at pH ≥ 6.8 (McDermott and Tompsett, 1954; Zhang et al., 2002). In-
deed, MIC decreases as pH falls based on the Henderson–Hasselbach re-
lationship (Zhang et al., 2002). Wemeasured the pH in pericardial ﬂuid
of 10 of the 11 patients using pH probes. The between-test %CV in pH
measurements at 8 different times for the same sample was ±3.27%,
which means that the pH measurements were highly precise. The pH
results for the several measurements in each patient's sample are
shown in Fig. 6A. The mean (±standard deviation) pericardial ﬂuid
pH was 7.34 ± 0.11, exactly the same as physiological pH. Since
pyrazinamide MICs are performed at pH 5.9, the actual MICs at
pH 7.34 were calculated using the Henderson–Hasselbach equation as
described by Zhang et al. (Gumbo et al., 2014a; Zhang et al., 2002;
Zhang and Mitchison, 2003). Fig. 6B shows that the pyrazinamide
peak concentrations were about 40-times lower than the pH-adjusted
MICs, with a median peak of 42·93 mg/L versus a median MIC of
800 mg/L (p b 0.0001).
4. Discussion
We have identiﬁed poor penetration and rapid clearance of rifampi-
cin in the infected space of TB pericarditis. There was delayed and
decreased penetration from the blood into pericardial ﬂuid, as demon-
strated by both the peak concentration achieved and the time to maxi-
mum concentration. The reasons for this are unclear, but could include
thickened pericardial layers, or ﬁbrosis, among several possibilities.
The rapid clearance, compared with plasma is a surprise, given
rifampicin's well-known extraction from the blood and metabolism by
hepatocytes. We speculate that this is likely due to an active physiolog-
ical process such as transport out of the pericardium. The consequences,
however, are concerning, given that rifampicin, in consort with
pyrazinamide, is the primary drug associated with sterilizing effect in
the standard TB treatment regimen. We found that the non-protein
bound peak concentrations achieved in pericardium were below MICs
encountered in Cape Town clinical historical Mtb isolates. AUCs were
also very low,whichmeans theAUC-to-MIC ratioswere also low. There-
fore, there is likely to be little microbial kill from rifampicin at concen-
trations achieved with current doses in the standard regimen (Gumbo
et al., 2015a; Pasipanodya and Gumbo, 2011; Gumbo et al., 2007a;
Pasipanodya et al., 2013; Chigutsa et al., 2015). Given the gap between
non-protein bound peak and MICs, and the relationship of peak-to-
MIC ratios for optimal rifampicin kill and suppression of resistance
(Pasipanodya and Gumbo, 2011; Gumbo et al., 2007a; Pasipanodya
et al., 2013), it is unlikely that escalating the rifampicin dose alone
would be feasible to increase peak-to-MIC ratio to ranges that could
provide sterilizing effect in TB pericarditis without causing toxicity, pre-
senting a challenge in treating this condition.
Secondly, the pyrazinamide concentrations were approximately
similar to those in plasma. However, this is substantially lower than
the concentrations associated with effective microbial kill at the site of
Fig. 2. Rifampicin concentrations in the blood and pericardial ﬂuid. The p-values shown throughout are for theMann–Whitney test, and compared the total drug concentrations in plasma
versus pericardial ﬂuid, and not the free drug. A. The concentration–time proﬁles of rifampicin in pericardium and in the blood over a 24 h dosing interval. The time tomaximum concen-
trationwas longer in pericardial ﬂuid,while the peak concentrationswere blunted. B. Clearance of rifampicin from pericardial ﬂuid (PF) and plasma for each patient. Themedian clearance
from the blood was 7.82 (range: 7.79–7.84) L/h while that in pericardial ﬂuid was 9.49 (range: 6.30–13.14) L/h. C. The 0–24 h AUC for total drug concentrations was lower in pericardial
ﬂuid than in plasma; the free drug concentrations were even lower. D. Total rifampicin peak concentrations achieved in pericardial ﬂuid are lower than in plasma; free concentrations are
substantially lower. E. Comparison of free rifampicin peak concentrations to MICs demonstrates that the maximum concentrations achieved in pericardial ﬂuid are lower than MICs.
Thus, as the concentrations are cleared from the pericardium the gap between drug concentration and MIC rapidly widens.
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trated 17–22-fold, compared to plasma, which allows the pyrazinamide
to achieve the peak concentrations and AUC-to-MIC ratios associated
with optimal sterilizing effect in cavitary TB (Gumbo et al., 2009;
Pasipanodya et al., 2013; Conte et al., 1999). Indeed, optimal efﬁcacy is
achieved at a pyrazinamide AUC-to-MIC ratio of ~210 at site of infectionbased on hollow ﬁber systemmodel of TB, which has a quantitative pre-
dictive accuracy of 94% of clinical therapeutic values (Gumbo et al.,
2009; Pasipanodya et al., 2013; Gumbo et al., 2015b; Gumbo et al.,
2015c). Median AUC-to-MIC ratios were ≤1 after adjusting for pH. Sim-
ilarly, themedian peak concentration toMIC ratio is unlikely to produce
much microbial kill even under optimal pH conditions (Pasipanodya
Fig. 3. Ethambutol concentrations in plasma and pericardial ﬂuid (PF). The concentration time proﬁles of ethambutol total concentration over 24 h demonstrate reduced penetration of
ethambutol. Clearance from pericardium was slightly lower than plasma (15.91 versus 14.77 L/h). Despite the lower clearance from pericardial ﬂuid, the median AUC0–24 in pericardial
ﬂuid was 17.83 mg∗h/L compared to 29.51 mg∗h/L in plasma, a 40% reduction. The median total ethambutol peak concentration was 0.87 mg/L in pericardial ﬂuid compared to
1.84 mg/L in plasma, and was thus 53% lower. Since ethambutol is 30% protein bound, this means the free peak concentration in pericardium is a median of 0.61 mg/L. The non-protein
bound peak ethambutol concentrations were lower than MICs for most patients.
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concerning given that pyrazinamide has no antimicrobial effect at phys-
iological pH and only works at a pH below 6.0 (Gumbo et al., 2009;
McDermott and Tompsett, 1954; Zhang et al., 2002; Zhang and
Mitchison, 2003). Direct measurement of pericardial ﬂuid pH in the pa-
tients revealed that in fact the pH was slightly alkaline and similar tophysiologic pH. At this pH, we expect little to no pyrazinamide effect
on Mtb in pericardial ﬂuid. Since rifampicin concentrations are also
low, and the sterilizing effect of the current regimen is driven by the
synergistic effect of these two drugs, this suggests that theremay be lit-
tle to no sterilizing effect during treatment of pericardial TB
(Pasipanodya et al., 2013; Chigutsa et al., 2015).
Fig. 4. Isoniazid concentrations in plasma and pericardial ﬂuid (PF). The concentration time proﬁles of total concentration over 24 h demonstrate matching concentration. Clearance from
pericardiumwas similar between plasma and pericardial ﬂuid. Themedian pericardial ﬂuid AUC0–24 in pericardial ﬂuid was 19.78 mg∗h/L compared to 18.75 mg∗h/L in plasma. The me-
dian total pericardial peak concentration was 2.12mg/L in pericardial ﬂuid and 2.44mg/L in plasma, virtually the same. Isoniazid penetrated well into pericardial ﬂuid and achieved con-
centrations of at least 64-fold higher than MICs.
1646 J. Shenje et al. / EBioMedicine 2 (2015) 1640–1649Thirdly, ethambutol concentrations were also lower in pericardial
ﬂuid compared to plasma concentrations, due to reduced penetration.
Similar to rifampicin, pyrazinamide, and isoniazid, ethambutolpenetration from plasma into pericardial ﬂuid varied by as much as
50% between patients. This additional variability needs to be taken
into account when designing optimal doses. The result of the low
Fig. 5. Pyrazinamide concentrations in plasma and pericardial ﬂuid. While pericardial ﬂuid pyrazinamide peak concentration was somewhat delayed, it nevertheless reached the same
level as in plasma. Pyrazinamide clearance from the pericardium was similar to that from plasma. The median pericardial ﬂuid AUC0–24 in pericardial ﬂuid was 815.6 mg∗h/L compared
to 687.90 mg∗h/L in plasma. The median total pericardial peak concentration was 38.45 mg/L in pericardial ﬂuid and 40.59 mg/L in plasma.
1647J. Shenje et al. / EBioMedicine 2 (2015) 1640–1649ethambutol concentrations, when added to low rifampicin and
pyrazinamide concentrations, means that effectively the drug concen-
trations of the majority of drugs in the regimen are suboptimal.
Fourthly, isoniazid concentrations in pericardium appear to be the
most favorable. Indeed it achieved similar concentrations to those in
plasma, to achieve both peak and AUCs in the range associated with
positive outcomes in other types of TB. In addition, the clearance was
similar to that from plasma; thus isoniazid pharmacokinetics in this
compartment can easily be inferred from those in the blood. From the
data identiﬁed in this pilot study, the doses of isoniazid for the treat-
ment of TB pericarditis likely need no change.
Given the foregoing it means the current rifampicin, isoniazid, eth-
ambutol, and pyrazinamide combination regimen is a “one trick
pony”. Only isoniazid seems to penetrate into pericardial ﬂuid to ade-
quate concentrations. However, we have shown elsewhere that at low
rifampicin concentrations such as those in pericardial ﬂuid, isoniazid
antagonizes rifampicin efﬁcacy in a concentration-dependent fashion
(Chigutsa et al., 2015; Conte et al., 1999; Srivastava et al., 2011b). Thus
one consequence of a low rifampicin concentration but adequate isoni-
azid concentration could be drug antagonism, further compromising
the regimen. We likely have an anti-TB drug regimen that is of limitedutility in TB pericarditis, based on the poor penetration of the key ster-
ilizing effect drugs. Indeed, in the IMPI trial, and IMPI registry studies,
there were high rates of mortality from TB pericarditis and disseminat-
ed TB, encountered while patients are on therapy. Given that we have
now shown that proven TB pericarditis is a high bacillary burden dis-
ease, with about 106 colony forming units per milliliter, and that TB
pericarditis mortality is higher at CD4+ counts below 200 cells/mL
(Pasipanodya et al., nd), it means that we are unlikely to derive beneﬁt
from the immune system to sterilize the pericardial space of this large
bacterial burden. Thus antibiotics with high efﬁcacy are needed. For
drugs such as rifampicin and pyrazinamide, the gap could be too wide
to be achieved by further dose optimization. Nevertheless, attempts at
dose optimization for these drugs should still be made. We propose
that a new regimen speciﬁc to TB pericarditis that is developed using
the PK/PD aspects speciﬁc to TB pericarditis, is needed. Indeed, there is
need for drugs that are rapidly bactericidal and can sterilize theMtb en-
countered in TB pericarditis within weeks rather than months.
Our study has several limitations. First is the small sample size. It is
possible that with larger studies different results could be obtained.
However, given the need to leave a pigtail catheter for the intensive
pharmacokinetic sampling, it was important to limit the number of
Fig. 6. The pH of pericardial ﬂuid and pyrazinamide MICs. A. The pH in pericardial ﬂuid
in each patient was measured 8 times in triplicate; shown are the mean values and stan-
dard deviation. The D'Agostino and Pearson omnibus normality test p-value was 0.991,
which means that the pH values in the pericardial ﬂuid were normally distributed. All
the pH values were greater than 7.0, and indeed were similar to the pH of 7.365 in the
blood, which is slightly alkaline. B. Pyrazinamide MICs measured at pH 5.9 were used
calculate the actual MICs at physiological pH based on the relationship between the active
moiety pyrazinoic acid (POA; anion POA−) and HPOA in theHandersen–Hasselbach equa-
tion (POA pKa = 2.9), as demonstrated by Zhang et al. (2002). At pH 5.90 the % of the
HPOA is 0.1% compared to 0.00363% at pH 7.34, a 27.54-fold change, which is the factor
used to calculate the MIC value at pH 7.34 based on that identiﬁed at pH 5.9. This leads
to an MIC with a median 18.6-fold higher than the median peak concentrations; indeed
the highest pyrazinamide peak concentration was 4-fold lower than the lowest MIC.
1648 J. Shenje et al. / EBioMedicine 2 (2015) 1640–1649patients exposed to this procedure. Thus, our results should be
interpreted with caution. However, given the dramatic nature of the re-
sults, and that rifampicin was actually studied in a total of 27 patients
and showed the same results, it is very likely that the same results
will be obtained in larger studies. Second, we did not measure the
MICs directly from the patients in the study. However, given the num-
bers of patients, the number of Mtb isolates would have been too
small to identify a good enough distribution, and we would still have
had to rely on MICs from larger studies. Third, use of steroids could
have altered the ability of antibiotics to penetrate into pericardium.
However, there were no apparent differences in antibiotic concentra-
tions between patients who received steroids and those who did not.
In summary, this is the ﬁrst study of its kind tomeasure anti-TB drug
concentrations in pericardial ﬂuid. The study also related these concen-
trations to protein binding, and the pH encountered in TB pericardial
ﬂuid. Concentrations of rifampicin, ethambutol and pyrazinamide
were dramatically lower relative to MICs.Author Contributions
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